Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* A positive test for SARS-CoV-2~* A GP consultation for deteriorating COVID-19 symptoms~Additional inclusion criteria in order to be eligible for randomization to the trial:~- Exercise-induced desaturation, defined as SpO2\<92% (\<90% for COPD patients) and/or an absolute drop of ≥4% in SpO2 after a 1-minute sit-to-stand test~OR~- SpO2\<92% (\<90% for COPD patients) in rest with GP's and patient's shared decision to keep patient at home despite this in itself being an indication for referral to hospital~Exclusion Criteria:~* Inability to understand and sign the written consent form~* Inability to perform saturation measurements or sit-to-stand test~* Not willing to be admitted to hospital~* On the discretion of the recruiting clinician if he or she deems a patient not eligible~The following criterion will be used to exclude patients from randomization to the trial:~* Contra-indication for dexamethasone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): 6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms
- Control (Type: NO_INTERVENTION): Only remote monitoring

Based on this trial design, predict the completion outcome and termination type (if applicable).